Heather Preston - 24 Jun 2021 Form 4 Insider Report for Akouos, Inc.

Role: Director
Signature: /s/ Karoline Shair, as attorney-in-fact for Heather Preston
Issuer symbol: N/A
Transactions as of: 24 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 25 Jun 2021, 16:37:45 UTC
Previous filing: 23 Jun 2021
Next filing: 22 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKUS	Stock Option (right to buy)	Award	$0	+16,000		$0.000000	16,000	24 Jun 2021	Common Stock	16,000	$13.39	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was granted on June 24, 2021. The shares underlying the option will fully vest on the earlier of (i) June 24, 2022 and (ii) the date of the Issuer's 2022 annual meeting of stockholders.
F2	The option was granted to the Reporting Person, a managing partner of Pivotal BioVenture Partners Fund I, L.P. (the "Fund") and an officer of Pivotal bioVenture Partners Investment Advisor, LLC (the "Investment Adviser"), the Fund's investment adviser, in connection with her service as a member of the Board of Directors of the Issuer. Pursuant to the policies of the Investment Adviser, the Reporting Person has assigned her rights in respect of the option to the Investment Adviser. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein, if any.

Content

This option was granted on June 24, 2021. The shares underlying the option will fully vest on the earlier of (i) June 24, 2022 and (ii) the date of the Issuer's 2022 annual meeting of stockholders.

The option was granted to the Reporting Person, a managing partner of Pivotal BioVenture Partners Fund I, L.P. (the "Fund") and an officer of Pivotal bioVenture Partners Investment Advisor, LLC (the "Investment Adviser"), the Fund's investment adviser, in connection with her service as a member of the Board of Directors of the Issuer. Pursuant to the policies of the Investment Adviser, the Reporting Person has assigned her rights in respect of the option to the Investment Adviser. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein, if any.